Surzetoclax
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Surzetoclax
- Molecular weight
- 1,039.65
- Structure (SMILES)
- CO[C@@H]1CC[C@@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN5CC6=C(c7ccc(Cl)cc7)CC(C)(C)C[C@H]6OCCCOC[C@@H]5C4)cc3N3CCCOc4nc5[nH]ccc5cc43)cc2[N+](=O)[O-])OC1
- a 1944798 0
- A-1944798.0
- abbv 453
- ABBV 453 [WHO-DD]
- abbv 453 who dd
- ABBV-453
- d erythro hexitol 1 5 anhydro 6 4 4 4as 10ar 14 4 chlorophenyl 1 2 4a 5 8 9 10a 11 13 15 decahydro 12 12 dimethyl 7h 12h pyrazino 2 1 g 1 5 8 benzodioxaazacycloundecin 3 4h yl 2 3 4 dihydro 2h pyrrolo 3 2 5 6 pyrido 2 3 b 1 4 oxazepin 1 7h yl benzoyl amino sulfonyl 2 nitrophenyl amino 3 4 6 trideoxy 2 o methyl
- D-erythro-Hexitol, 1,5-anhydro-6-[[4-[[[4-[(4aS,10aR)-14-(4-chlorophenyl)-1,2,4a,5,8,9,10a,11,13,15-decahydro-12,12-dimethyl-7H,12H-pyrazino[2,1-g][1,5,8]benzodioxaazacycloundecin-3(4H)-yl]-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)benzoyl]amino]sulfonyl]-2-nitrophenyl]amino]-3,4,6-trideoxy-2-O-methyl-
- surzetoclax
- Surzetoclax
- surzetoclax [INN]
- SURZETOCLAX [USAN]
- surzetoclax inn
- surzetoclax usan
- CAS registry numbers
- 2858632-01-4
- ChEMBL ID
- CHEMBL6068032
- InChIKey
- AWGQQZVAXXLVMT-ORYVFAGJSA-N
- PubChem compound IDs
- 169450714
- FDA ingredient codes (UNII)
- C3TU3CHH6L
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -toclax
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0005070
- Calculated partition coefficient (XLogP)
- 7.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 73
- Molecular formula
- C53H63ClN8O10S
- Monoisotopic mass
- 1038.4076391
- Natural product
- No
- Recorded assays
- 4
- Active assays
- 4
Active assay types
- Confirmatory
Related records
Trials (3)
- A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
In development for (1)
- Neoplasm Phase 2